Key result
Direct oral anticoagulants have shown non-inferiority in preventing thromboembolic events and superior safety in bleeding compared to warfarin, with apixaban and dabigatran showing superiority.
Why the study?
Do direct oral anticoagulants improve safety and efficacy compared to warfarin in patients requiring anticoagulation, including those with advanced chronic kidney disease?
Do direct oral anticoagulants improve safety and efficacy compared to warfarin in patients requiring anticoagulation, including those with advanced chronic kidney disease?
DOACs offer a safer and more convenient alternative to warfarin for anticoagulation, though their specific role in advanced chronic kidney disease requires further exploration.
Answers are grounded in this paper and cite their sources.
May support DOAC preference in advanced CKD; leaves open dedicated RCTs for severe renal impairment.
With the advent of the direct oral anticoagulants (DOACs), patients requiring anticoagulation for common conditions such as atrial fibrillation and venous thromboembolism no longer need to worry about dietary restrictions or regular monitoring of the international normalized ratio which complicated warfarin treatment. Switching from warfarin to apixaban, a DOAC, has been shown to improve patient satisfaction by reducing treatment burden [1]. The clotting factor Xa inhibitors (apixaban, rivaroxaban, and edoxaban) and the direct thrombin inhibitors (argatroban and dabigatran) have shown non-inferiority in preventing thromboembolic events and a superior safety profile in terms of bleeding in several trials when compared to warfarin [2-6]. Furthermore, apixaban and dabigatran have even shown superiority in preventing stroke or systemic embolism [3,6].
No takes yet. Share an insight, caveat, or question.
Ionescu et al. (2021) conducted a review in Advanced Chronic Kidney Disease, atrial fibrillation, venous thromboembolism. Direct Oral Anticoagulants (DOACs) vs. warfarin was evaluated. Direct oral anticoagulants have shown non-inferiority in preventing thromboembolic events and superior safety in bleeding compared to warfarin, with apixaban and dabigatran showing superiority.
Synapse has enriched 10 related papers. Consider them for comparative context: